Core Viewpoint - Baiyunshan, a listed pharmaceutical company in A-shares, has announced the establishment of the Guangzhou Guangyao Guangkai Venture Capital Fund, which has completed its business registration and obtained a business license in January 2026, with a total initial capital contribution of 120 million yuan [1][3]. Group 1: Fund Establishment and Contributions - The Guangzhou Guangyao Guangkai Venture Capital Fund has a registered capital of 200 million yuan, with the initial capital contribution of 120 million yuan completed by the partners [3][5]. - The fund's contributors include Guangkai Fund (50%), Guangyao Phase II Fund (48.75%), and Guangyao Capital (1.25%) [5]. - Baiyunshan's investment in the Guangyao Guangkai Fund aligns with its strategy to expand investment scale and diversify risks in the biopharmaceutical sector [5]. Group 2: Investment Progress and Strategy - Baiyunshan has invested a total of 587 million yuan across three private equity funds, with the largest investment being 390 million yuan in the Guangzhou Guangyao Chuantou Venture Capital Fund [6]. - The company aims to strengthen its position in innovative drugs, modern traditional Chinese medicine, and high-end medical devices through early and small investments in promising enterprises [5][6]. - The establishment of the Guangyao Guangkai Fund is expected to accelerate Baiyunshan's transition from traditional business models to technology-driven development, laying a solid foundation for high-quality growth [5].